Is It Possible to Select the Sex of the Baby in Surrogacy Using PGT-A (PGTA) Testing? (2026)

You’ve just received your screening report. Each embryo is listed by number, chromosomal status, and right there in black and white: XX or XY. Your mind jumps ahead. You picture a daughter. Or a son. And then the question lands: can you actually choose?

Quick Overview: What PGT-A Can and Cannot Do (As of 2026)

Picture IVF (in vitro fertilization) screening as a filter, not a design tool. It checks each embryo for the correct number of chromosomes and flags abnormalities. Along the way, it reads the 23rd pair, so your report can indicate XX or XY. That data exists on the page.

What it cannot do is:

• guarantee a pregnancy
• promise a live birth
• override regulations in your jurisdiction
• assess mitochondrial function
• epigenetic programming, or 
• uterine receptivity

PGT-A gives you a sharper chromosomal picture. Whether your program allows baby sex selection based on that data depends on where you are and which facility you work with.

PGT-A / PGTA Explained: Preimplantation Genetic Testing for Aneuploidy

Before your team can decide which candidate to transfer, they need to understand what’s happening at the chromosomal level. Preimplantation genetic testing for aneuploidy is a laboratory analysis of a small cell sample, designed to count chromosomes and flag abnormalities invisible under a microscope.

What “Aneuploidy” Means and Why It Matters

Every healthy human cell carries 46 chromosomes in 23 pairs. Aneuploidy means a wrong count. Most abnormal embryos fail to implant or end in early loss. For egg providers over 38, more than half of all results may show these errors, which is why screening exists.

Euploid Embryo vs Aneuploidy: High-Level Interpretation

A euploid embryo carries the expected 46 chromosomes. It offers a statistically stronger chance of implantation and lower loss rates compared to untested transfers. But results also include mosaic findings, a mix of normal and abnormal cells, which clinicians evaluate case by case. A normal result does not guarantee a live birth. Biology doesn't deal in certainty. Preimplantation genetic testing for aneuploidy refines the odds; it doesn't rewrite them.

Embryo Quality vs Chromosomal Status: Why Both Are Discussed

Embryo quality and chromosomal status overlap but aren't identical. Labs grade based on visual morphology. A beautifully graded embryo can still be abnormal. A visually average embryo can be a euploid embryo that produces a healthy pregnancy. Morphological assessment and PGT-A results together give your team their best picture.

IVF (In Vitro Fertilization) Steps That Lead to PGT-A

Chromosomal screening sits at the end of a clinical sequence. Each prior step narrows the field, so the number of candidates available for testing depends on how every stage goes.

Ovarian Stimulation and Egg Retrieval

Ovarian stimulation uses injectable medications to produce multiple mature eggs over roughly 10 to 14 days. Egg retrieval follows a trigger injection, performed under sedation in 15 to 20 minutes. Not every egg collected will be mature, and not every mature egg will fertilize after retrieval. Ovarian stimulation aims for volume because numbers narrow at every step from stimulation through egg retrieval.

Fertilization and ICSI: Why Clinics May Use ICSI

After eggs arrive in the lab, sperm is introduced. ICSI (intracytoplasmic sperm injection) is often preferred because it reduces residual sperm DNA on the outer shell that could interfere with testing accuracy. ICSI doesn't change what screening detects; it ensures a cleaner sample. Fertilization through either method produces candidates that develop over five to six days. ICSI is standard when sperm count or motility is low.

From Embryo to Blastocyst: When Testing Is Possible

By day five or six, a healthy embryo reaches the blastocyst stage, with an inner cell mass (future fetus) and an outer trophectoderm layer (future placenta). Testing happens at blastocyst because the outer layer provides enough cells to sample safely. Earlier stages lack sufficient cellular material. Not every candidate reaches blastocyst; those that stall earlier reveal limited developmental potential.

Embryo Biopsy and the Science Behind Results

Once an embryo reaches the right stage, a sample can be collected and sent for analysis. This step is the bridge between the laboratory and the genetics report you'll eventually read.

Embryo Biopsy: What Is Taken and Why

An embryo biopsy removes approximately five to ten cells from the outer layer using a fine laser and micropipette. The embryo is then vitrified while the sample travels to a genetics lab. When performed by experienced teams, risk is low but not zero. This embryo biopsy is a calculated trade off: small procedural risk for significant diagnostic information. One embryo biopsy gives one snapshot.

Trophectoderm Sampling: What It Represents (High-Level)

The trophectoderm is the outer cell layer destined to become placental tissue, not the inner cell mass that will form the baby. Mosaicism can mean the trophectoderm results don't perfectly match the true genetic profile. The sample is a proxy — an informed one, but still a proxy. Clinicians interpreting PGT-A results work within this limitation.

Limitations and Uncertainty: Why Results Are Not "Perfect"

No screening test is infallible. Preimplantation genetic testing for aneuploidy works with limited cells from one location. False positives and false negatives both occur, though current platforms have improved significantly. Respect the value of this screening. Respect its boundaries too.

Sex Chromosomes (XX / XY) and Baby Sex Selection: What's Actually Possible

You want to know: if the lab can see whether a result is XX or XY, can you pick? The science makes identification straightforward. Everything after that gets complicated.

How PGT-A Can Report Sex Chromosomes

When a lab screens all 23 chromosome pairs, the 23rd pair reveals sex chromosomes: XX or XY. Labs don't run a separate test; this data emerges from the same analysis. Whether your facility shares that information and whether you can use it depends on policy and law, not laboratory capability. The sex chromosomes appear on the report automatically.

Baby Sex Selection vs Embryo Selection for Medical Reasons

Baby sex selection for medical reasons, such as avoiding conditions like hemophilia or Duchenne muscular dystrophy, is widely accepted. Baby sex selection for nonmedical reasons sits in different territory. Some jurisdictions permit it. Others ban it. Many facilities decline regardless of local law, based on their own guidelines. The distinction between medical and nonmedical purposes is the variable that determines what's possible for you. Embryo selection on medical grounds rarely sparks controversy; embryo selection on preference does.

Common Misconceptions: "If We Know XX/XY, We Can Always Choose"

Knowing is not choosing. The lab can tell you which XX / XY result each candidate carries. But XX / XY data on the page is not the same as permission to act on it. That does not mean your clinic will transfer based on preference. You may only have one or two chromosomally normal candidates. Your preferred sex may not be represented. You may only have one or two viable options overall. Or your strongest embryo may carry the chromosomes you didn't prefer.

Transfer Decisions and Outcomes (No Guarantees)

Screening results in hand, the conversation shifts to what happens next and what outcomes you can realistically expect.

Embryo Selection and Single Embryo Transfer: Why Policies Differ

Single embryo transfer has become the standard recommendation. When screening results are available, embryo selection typically prioritizes chromosomal normality first, then morphology. If a program permits considering sex, it enters only after clinical metrics are satisfied. No responsible program sacrifices embryo quality for preference. Single embryo transfer policies vary; some facilities strictly enforce one per cycle.

Implantation Rate: What Influences It Beyond PGT-A

Selecting a chromosomally normal candidate does improve the implantation rate per transfer, with studies through 2025 suggesting rates around 60 to 70 percent for screened single transfers. The implantation rate depends on more than chromosomes: endometrial receptivity, transfer timing, the surrogate's uterine environment, and vitrification quality all contribute.

Miscarriage Risk: What PGT-A May Reduce and What It Cannot Eliminate

By prioritizing normal candidates, PGT-A may reduce miscarriage risk attributable to wrong chromosome counts. Research supports a lower loss rate in screened cycles. However, miscarriage risk extends beyond chromosomes: uterine anomalies, immunological factors, infections, and unexplained causes all play roles. Lower risk is not zero risk.

Clinic Policy, Legal Restrictions, and Ethics (2026)

Science tells you what's chromosomally possible. Policy, law, and professional standards tell you what's permitted.

Clinic Policy: What Clinics May Allow or Decline

Clinic policy on disclosing chromosomal sex results varies enormously. Some facilities release full reports routinely. Others withhold data unless a medical indication justifies it. Before committing, ask directly what this clinic policy covers. Will they prioritize a candidate based on preference if multiple normal options exist? Current regulations and policies may vary. Clinic policy shapes your experience as much as success rates.

Legal Restrictions: Why Rules Differ by Jurisdiction

Legal restrictions on nonmedical sex determination in assisted reproduction are a patchwork. Some countries prohibit it entirely; others leave decisions to clinics. The table below compares selected surrogacy destinations. These legal restrictions may change, and individual verification with a qualified professional is essential. The legal restrictions shown are general and current as of 2026.

Country	Commercial Surrogacy	Screening Offered	Nonmedical Sex Preference Policy	Key Notes (2026)
Armenia	Yes, regulated	Yes, select clinics	May be restricted; depends on facility	Surrogacy law exists; testing access expanding
Belarus	Yes, legal framework	Yes, major centers	Generally restricted	Framework specifies surrogacy eligibility
Georgia	Yes, heterosexual married couples	Yes, widely available	May be restricted; facility discretion	Surrogacy legally recognized
Kazakhstan	Yes, specific legal provisions	Yes, established centers	Subject to facility guidelines	Framework supports surrogacy
Kyrgyzstan	Yes, legal basis	Select clinics	Policy varies	Testing options more limited
UAE	Yes, regulated	Yes, licensed clinics	Restricted for nonmedical purposes	Framework supports surrogacy

Ethics: How Programs Approach Non-Medical Sex Selection

Ethics in reproductive medicine rarely offer clean answers. Proponents of nonmedical selection argue for reproductive autonomy. Opponents raise concerns about gender bias and commodification. Most professional organizations distinguish between selection for genetic disease avoidance (accepted) and personal preference (debated). Program ethics frameworks vary, and the ethics of your specific program matter as much as the law. Understanding a program's ethics position before investing emotionally and financially is worth the effort. Embrymama approaches these questions with transparency.

Frequently Asked Questions

Making an Informed Decision in 2026

The technology to identify chromosomal sex during IVF (in vitro fertilization) exists. It works. But technology and permission are different things. Under current clinical practice, PGT-A gives you data, not permission. PGTA reveals chromosomal status, nothing more. Enter the process informed rather than hopeful. Know what the screening tells you. Know what your jurisdiction allows.

Not Sure What Applies to Your Case? Let's Review Your Options.

Every IVF and surrogacy journey carries its own combination of medical history, jurisdiction, and personal priorities. Rather than guessing, get clarity. A confidential case review with the embrymama.com team can map your specific situation: which destinations fit your needs, what screening can offer, and what options may realistically be available. No pressure, no promises.